GET VOWST DOSING DETAILS

^aClostridioides difficile (C. diff) infection.

START YOUR PATIENT ON VOWST with VOWST Voyage™

DYSBIOSIS CAN MAKE RECURRENT C. DIFF^a GO EXTRA ROUNDS^1,2

AS EARLY AS FIRST C. DIFF RECURRENCE,
KNOCK IT OUT WITH THE

1-2

GUT
PUNCH

Prescribing VOWST following an antibiotic to deliver
superior efficacy vs an antibiotic alone^3-5

GET VOWST DOSING DETAILS

^aClostridioides difficile (C. diff) infection.

Peers and patients discuss
their struggles with rCDI and
how they found VOWST

See the video library

VOWST support programs
help patients
and providers along the way

Visit access and resources

VOWST oral dosing follows
standard-of-care antibiotics
and a laxative^3,4

See VOWST dosing

VOWST is proven efficacious
and well tolerated^3,7

See the details of VOWST clinical data

rCDI can be serious, including
risk of mortality⁸

See the risks rCDI may pose to your patients

Hear from Dr. Feuerstadt on
his approach to treating rCDI
with VOWST

Watch video

ABX, antibiotics; rCDI, recurrent C. diff infection.

References: 1. Jain N, Umar TP, Fahner A-F, Gibietis V. Advancing therapeutics for recurrent Clostridioides difficile infections: an overview of vowst's FDA approval and implications. Gut Microbes. 2023;15(1):2232137. doi:10.1080/19490976.2023.2232137 2. Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132. doi:10.1186/s12879-023-08096-0 3. VOWST [Prescribing Information]. Bridgewater, NJ: Aimmune Therapeutics, Inc. 02/2025. 4. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220-229. doi:10.1056/NEJMoa2106516 5. Cohen SH, Louie TJ, Sims M, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA. 2022;328(20):2062-2064. doi:10.1001/jama.2022.16476 6. Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information: Guidance for Industry. Center for Biologics Evaluation and Research, US Food and Drug Administration. Updated June 2016. Accessed October 25, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information 7. Sims MD, Khanna S, Feuerstadt P, et al; ECOSPOR IV Investigators. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Netw Open. 2023;6(2):e2255758. doi:10.1001/jamanetworkopen.2022.55758 8. Feuerstadt P, Stong L, Dahdal DN, Sacks N, Lang K, Nelson WW. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ. 2020;23(6):603-609. doi:10.1080/13696998.2020.1724117

ECOSPOR III
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff ^1-3
Primary Endpoint Recurrence at 8 weeks* Secondary Endpoints Adverse events within 24 weeks Recurrence at 4, 12, 24 weeks*
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)

ECOSPOR IV
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff ⁵
Primary Endpoint Adverse events within 24 weeks Secondary Endpoints Recurrence at 4, 8, 12, 24 weeks
Recurrence confirmed with C. diff toxin test or PCR and ≥3 unformed bowel movements per day over 2 days^*
10–42 days of vancomycin or 10–25 days of fidaxomicin

VOWST is the FIRST and ONLY FDA-approved live biotherapeutic product administered orally for the prevention of C. diff recurrence 3,4,6

Peers and patients discuss their struggles with rCDI and how they found VOWST

VOWST support programs help patients and providers along the way

VOWST oral dosing follows standard-of-care antibiotics and a laxative3,4

VOWST is proven efficacious and well tolerated3,7

rCDI can be serious, including risk of mortality8

Hear from Dr. Feuerstadt on his approach to treating rCDI with VOWST